SecBot SecBot
DEFA14A ·Filed Jun 10, 2026

VTVT

vTv Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001193125-26-265834
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine administrative filing correcting a missing Say-on-Pay proposal. No market-moving information. Monitor the June 26 meeting outcome for any unexpected opposition to director elections or compensation, though none are anticipated given management's unified recommendation.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.59
T+0 close · Jun 10, 2026 · via day close
Latest settled
+5.57%
T+60 · $33.35
Vs SPY
+1.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $31.59entry
  2. T+1 · 5mo ago +3.72%α +3.18% · $32.77
  3. T+5 · 5mo ago +7.38%α +6.94% · $33.92
  4. T+20 · 4mo ago +5.86%α +3.97% · $33.44
  5. T+60 · 2mo ago +5.57%α +1.18% · $33.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

vTv Therapeutics filed a DEFA14A to correct an inadvertent omission from its 2026 proxy statement, adding an advisory vote (Say-on-Pay) on executive compensation as Proposal 3. The annual meeting was adjourned from June 10 to June 26, 2026, without transacting any business, to allow shareholders time to review the new proposal. This is a routine administrative correction with no material financial or strategic impact.

Key Financial Metrics

Vote
say on pay
Meeting
2026-06-26

Key Facts

  • Original proxy statement (filed April 28, 2026) inadvertently omitted Proposal 3 for an advisory vote on executive compensation.
  • Annual meeting convened June 10, 2026 was adjourned immediately without any business transacted.
  • Adjourned meeting will resume June 26, 2026 at 11:00 AM ET via virtual webcast.
  • Record date remains April 14, 2026; voting deadline extended to June 24, 2026.
  • Board recommends FOR all three proposals: director election, auditor ratification, and Say-on-Pay.
  • Proposal 1 (director election) and Proposal 3 (Say-on-Pay) are non-routine (broker discretionary voting prohibited).

Financial Impact

No financial figures disclosed; purely procedural proxy correction.

Risk Factors

  • No material risks identified; routine filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-265834
Document: 0001193125-26-265834-index-headers.html0001193125-26-265834
Document: 0001193125-26-265834-index.html0001193125-26-265834
Document: 0001193125-26-265834.txt0001193125-26-265834

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026